Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434286 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2D6USP2ALDH1A1LMNA | |
| SCHEMBL5432940 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2D6USP2ALDH1A1LMNA | |
| SCHEMBL14459062 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2D6USP2ALDH1A1LMNA | |
| SCHEMBL5437913 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2D6USP2ALDH1A1LMNA | |
| SCHEMBL5436464 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2D6USP2ALDH1A1LMNA | |
| SCHEMBL5445647 | 0.90 | USP2 (0.42) | CYP3A4CYP2D6USP2ALDH1A1LMNA | |
| SCHEMBL4755518 | 0.90 | USP2 (0.42) | CYP3A4CYP2D6USP2ALDH1A1LMNA | |
| SCHEMBL4755521 | 0.90 | USP2 (0.42) | CYP3A4CYP2D6USP2ALDH1A1LMNA | |
| SCHEMBL4755526 | 0.90 | USP2 (0.42) | CYP3A4CYP2D6USP2ALDH1A1LMNA | |
| SCHEMBL5443186 | 0.86 | CYP2D6 (0.39) | CYP3A4CYP2D6USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180959-A1 | Gabapentin analogues for fibromy algia and concomitant disorders | DOOLEY DAVID JAMES (US) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180959-A1 | Gabapentin analogues for fibromy algia and concomitant disorders | PKD2, CACNA1S, CACNA1B | CYP3A4 3218/4885CYP2D6 2665/4885USP2 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.